Andy Plump (Jeff Rumans for Endpoints News @ JPM19)

MD An­der­son emerges with strong ev­i­dence for nat­ur­al killer cell ther­a­py, and Take­da looks like a win­ner

As far as bi­o­log­i­cal brand­ing goes, it’s hard to beat nat­ur­al killer cells.

These im­mune re­spon­ders earned their moniker in the ’70s for their ap­par­ent abil­i­ty to kill virus­es and some tu­mor cells quick­ly and with­out ini­tial train­ing. And in re­cent years, as sci­en­tists be­gan re-en­gi­neer­ing T cells to at­tack eva­sive tu­mors and cre­at­ing the first CAR-T treat­ments, re­searchers start­ed se­ri­ous­ly ex­plor­ing how to do the same with nat­ur­al killers.

Endpoints News

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.